BRIGHT: Clinical Trial Open to Recruitment

Research FOR Patients
-For an informed and empowered opinion-

All the trials listed in our site have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for the continuous work in updating the listing.

BRIGHT

  1. SUB-TYPE OF MDS:Previously untreated higher-risk MDS, AML or CMML
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: Glasdegib, Azacitidine
  4. Aims and benefits: PGlasdegib disrupts cancer stem cell survival. This has the potential to reduce the development of drug resistance and prevent relapse. This is a Phase 1b study aimed at determining the safety and effectiveness of Glasdegib in combination with Azacitidine in this specific patient group.

  1. Primary outcome measures: 
    Assessing complete remission rates and adverse events.
  2. Secondary outcome measures:
    To determine response rates and the rates of haematologic improvement.
  3. Basic inclusion criteria:
    • Clinical indication for treatment with Azacitidine.
    • Previously untreated higher-risk (Intermediate, high risk or very high risk) MDS, AML or CMML.
  4. Basic exclusion criteria:
    • Patients with AML who are suitable for standard induction chemotherapy as first line treatment.
    • Known active CNS leukaemia.
    • Prior treatment with a smoothened inhibitor and/or a hypomethylating agent.
  5. Trial sites/locations and name of physician in charge of trial:
    • Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool
    • King’s College Hospital NHS Foundation Trust, London
    • Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne
    • Oxford University Hospitals NHS Foundation Trust, Oxford

Please read information and always discuss trial information with your own physician.

Free donations by shopping

Sign-up to Download our Free Patient Handbook!

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

MDS UK Patient Support Group will use the information you provide on this form to be in touch with you and to provide updates.